Company news

Arrowhead Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK

April 2, 2023

Arrowhead Receives FDA Fast Track Designation for ARO-APOC3

March 19, 2023

Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference

March 2, 2023

Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

February 27, 2023

Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

February 14, 2023

Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results

February 5, 2023

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis

February 1, 2023

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results

January 24, 2023

Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

January 8, 2023

Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

December 20, 2022

Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference

December 20, 2022

Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen

December 19, 2022

Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

December 7, 2022

Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

December 7, 2022

Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results

November 27, 2022

Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences

November 20, 2022

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results

November 13, 2022

Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones

November 8, 2022

Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline

November 6, 2022

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3

October 10, 2022

Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences

August 31, 2022

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis

August 16, 2022

Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results

August 3, 2022

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results

July 19, 2022

Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

July 4, 2022

Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences

June 6, 2022

Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics

May 25, 2022

Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results

May 9, 2022

Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives

May 8, 2022

Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences

May 1, 2022

Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors

May 1, 2022

Arrowhead Pharmaceuticals to Host Pulmonary R&D Day

April 26, 2022

Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia

April 25, 2022

Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market

April 24, 2022

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results

April 19, 2022

Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences

March 31, 2022

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases

March 23, 2022

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma

March 14, 2022

Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

February 23, 2022

Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

February 17, 2022

Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

February 16, 2022

Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results

February 1, 2022

Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline

January 23, 2022

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results

January 20, 2022

Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

January 11, 2022

Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities

December 19, 2021

Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences

November 29, 2021

Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results

November 21, 2021

Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD

November 21, 2021

Arrowhead Announces JNJ-75220795 in Development for NASH

November 16, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.